430 related articles for article (PubMed ID: 16849589)
1. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
[TBL] [Abstract][Full Text] [Related]
2. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
Reddy BS; Wang CX; Kong AN; Khor TO; Zheng X; Steele VE; Kopelovich L; Rao CV
Cancer Res; 2006 Apr; 66(8):4542-6. PubMed ID: 16618783
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
5. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.
Swamy MV; Cooma I; Reddy BS; Rao CV
Int J Oncol; 2002 Apr; 20(4):753-9. PubMed ID: 11894121
[TBL] [Abstract][Full Text] [Related]
6. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Zheng X; Cui XX; Avila GE; Huang MT; Liu Y; Patel J; Kong AN; Paulino R; Shih WJ; Lin Y; Rabson AB; Reddy BS; Conney AH
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5480-7. PubMed ID: 17875778
[TBL] [Abstract][Full Text] [Related]
8. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
Reddy BS; Patlolla JM; Simi B; Wang SH; Rao CV
Cancer Res; 2005 Sep; 65(17):8022-7. PubMed ID: 16140976
[TBL] [Abstract][Full Text] [Related]
9. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Kawamori T; Rao CV; Seibert K; Reddy BS
Cancer Res; 1998 Feb; 58(3):409-12. PubMed ID: 9458081
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Raval M; Frank PG; Laury-Kleintop L; Yan G; Lanza-Jacoby S
J Surg Res; 2010 Oct; 163(2):e113-22. PubMed ID: 20538289
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Boolbol SK; Dannenberg AJ; Chadburn A; Martucci C; Guo XJ; Ramonetti JT; Abreu-Goris M; Newmark HL; Lipkin ML; DeCosse JJ; Bertagnolli MM
Cancer Res; 1996 Jun; 56(11):2556-60. PubMed ID: 8653697
[TBL] [Abstract][Full Text] [Related]
13. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
14. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
[TBL] [Abstract][Full Text] [Related]
15. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
Abou-Issa HM; Alshafie GA; Seibert K; Koki AT; Masferrer JL; Harris RE
Anticancer Res; 2001; 21(5):3425-32. PubMed ID: 11848504
[TBL] [Abstract][Full Text] [Related]
16. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
17. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
18. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
Narayanan NK; Narayanan BA; Reddy BS
Int J Oncol; 2005 Mar; 26(3):785-92. PubMed ID: 15703837
[TBL] [Abstract][Full Text] [Related]
19. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells.
Xiao H; Zhang Q; Lin Y; Reddy BS; Yang CS
Int J Cancer; 2008 May; 122(9):2115-24. PubMed ID: 18172863
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
